Biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) revealed on Friday that it has received a negative opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) regarding palovarotene as a potential treatment for fibrodysplasia ossificans progressiva (FOP).
This decision confirms the negative opinion given in January 2023.
Palovarotene is the first medicine submitted for regulatory approval for FOP. The disease causes continuous and permanent abnormal bone formation, leading to mobility loss and shortened life expectancy. No disease-modifying treatments are currently available in the EU.
Ipsen said that it remains committed to introducing a new treatment option for FOP and will continue regulatory processes in other countries, including the United States.
"We continue to believe that our Phase III MOVE trial, the first and largest study to be conducted in patients with FOP, has shown that palovarotene has the potential to reduce the new extra-skeletal bone formation caused by the disease and to slow its progression," said Howard Mayer, executive vice president and head of Research and Development for Ipsen.
Palovarotene is an investigational oral medicine targeting retinoic-acid receptor gamma. It received Orphan Drug and Breakthrough Therapy Designations from the US Food and Drug Administration (FDA) for the potential treatment of FOP, as well as orphan medicine designation from the EMA.
Melt Pharmaceuticals enters exclusive agreement with Catalent for Zydis fast-dissolve tech
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Sanofi granted Priority Review for EoE treatment in young children
Valneva secures USD32m IXIARO vaccine contract with US DoD
Sanofi's ALTUVIIIO gains Japanese approval as haemophilia A factor VIII therapy
Seagen and Astellas Pharma report positive outcomes in advanced bladder cancer trial
Mabwell's 9MW3011 receives US FDA Fast Track Designation
89bio receives FDA Breakthrough Therapy Designation for pegozafermin in NASH treatment
Hepagene Therapeutics' HPG7233 IND application receives US FDA approval
Pulmatrix PUR3100 investigational new drug application receives US FDA acceptance
BeiGene regains full rights to anti-PD-1 antibody TEVIMBRA (tislelizumab) from Novartis
Avacta completes sixth dose escalation in AVA6000 Phase 1 trial
European Commission grants authorisation to ViiV Healthcare's Apretude for prevention of HIV
Pfizer's LITFULO gains EC approval for treating severe alopecia areata in adolescents and adults